[Accepted Manuscript] Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.


Fofana, M.O.; Shrestha, S.; Knight, G.; Cohen, T.; White, R.G.; Cobelens, F.; Dowdy, D.W.; (2016) [Accepted Manuscript] Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model. Antimicrobial agents and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.00498-16 (In Press)

WarningThere is a more recent version of this item available.
[img] Text - Accepted Version
License:

Download (723kB)
[img]
Preview
Text - Accepted Version
License:

Download (972kB) | Preview

Abstract

Several infectious diseases of global importance - e.g. HIV, tuberculosis (TB) - require prolonged treatment with combination antimicrobial regimens, typically involving high-potency "core" agents coupled with additional "companion" drugs that protect against de novo emergence of mutations conferring resistance to the core agents. Often, the most effective (or least toxic) companion agents are re-used in sequential (first-line, second-line, etc…) regimens. We used a multi-strain model of M. tuberculosis transmission in Southeast Asia to investigate how this practice might facilitate the emergence of extensive drug resistance, i.e., resistance to multiple core agents. We calibrated this model to regional TB and drug resistance data using an Approximate Bayesian Computational approach. We reported the proportion of data-consistent simulations in which the prevalence of pre-extensively drug resistant (pre-XDR) TB - defined as resistance to both first-line and second-line core agents (rifampin and fluoroquinolones) - exceeded pre-defined acceptability thresholds (1-2 cases per 100,000 population by 2035). Using pyrazinamide (the most effective companion agent) in both first-line and second-line regimens increased the proportion of simulations exceeding the pre-XDR acceptability threshold seven-fold, compared to a scenario in which patients with pyrazinamide-resistant TB received an alternative drug. Model parameters related to emergence and transmission of pyrazinamide-resistant TB and resistance amplification were among those most strongly correlated with projected pre-XDR prevalence, indicating that pyrazinamide resistance acquired during first-line treatment subsequently promotes amplification to pre-XDR TB under pyrazinamide-containing second-line treatment. These findings suggest that appropriate use of companion drugs may be critical to preventing the emergence of strains resistant to multiple core agents.

Item Type: Article
Faculty and Department: Academic Services & Administration > Academic Administration
Academic Services & Administration > Library
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
URI: http://researchonline.lshtm.ac.uk/id/eprint/3429605

Available Versions of this Item

Statistics


Download activity - last 12 months
Downloads since deposit
46Downloads
55Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item